Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. reports developments for its personalized healthcare platform, which combines virtual primary care, mental health support, expert medical opinion services, and care navigation for employer, health plan, and consumer markets. Company updates often center on PlushCare, direct-to-consumer virtual healthcare access, Medicare Part B acceptance, and services aimed at primary care, clinical weight management, and behavioral health support.
Recurring ACCD news also covers operating and financial results, investor presentations, material agreements, shareholder voting matters, governance, capital-structure disclosures, and healthcare regulatory topics tied to Accolade's virtual care and navigation model.
Accolade, Inc. (NASDAQ: ACCD) reported a fiscal Q1 2021 revenue of $35.9 million, representing a 25% increase from $28.8 million in the same quarter last year. The growth was attributed to new customer acquisitions across various segments. The company introduced a pilot program with the Defense Health Agency, marking its entry into the federal government sector. Although the net loss decreased to $(14.0) million from $(15.9) million in Q1 2020, the adjusted gross margin fell to 38.3%. The company provided guidance for Q2 2021 and full-year fiscal 2021.
Accolade, Inc. (NASDAQ: ACCD) has successfully closed its initial public offering, offering 11,526,134 shares of common stock at a public price of $22.00 per share. This includes the full exercise of the underwriters' option to purchase an additional 1,503,408 shares. Major underwriters include Goldman Sachs, Morgan Stanley, and BofA Securities. The offering will aid Accolade in providing personalized healthcare solutions and enhancing its marketplace presence. This IPO allows the company to navigate the healthcare system and improve consumer engagement.